AUS
NZ
UK
CA
USA
IND
Highlights
- The GLP-1 market for obesity and diabetes treatments is gaining momentum, with Novo Nordisk and Eli Lilly leading the space.
- Citi experts highlight increased prescriptions for obesity drugs like Wegovy and diabetes treatments such as Ozempic and Rybelsus, reflecting rising demand.
- Positive feedback from clinical trials and direct-to-consumer campaigns boosts optimism for further growth in Novo Nordisk's and Eli Lilly's portfolios.
The Healthcare sector has been abuzz with discussions surrounding the GLP-1 market, particularly in relation to treatments for obesity and diabetes. Key players in the space, such as Novo Nordisk and Eli Lilly, have garnered significant attention. Experts from Citi have expressed a favorable outlook for these companies, even as they navigate certain supply challenges.
Citi’s data highlights a substantial increase in prescriptions for obesity and diabetes medications. There was a notable rise in prescriptions for obesity drugs, such as Wegovy, and an uptick in diabetes treatments, including Ozempic and Rybelsus. These trends underscore the growing demand for medications that address these prevalent health conditions.
Looking ahead, Citi forecasts robust sales in the coming year for both Novo Nordisk and Eli Lilly (NYSE:LLY). With the ongoing demand for diabetes and obesity treatments, both companies are positioned to see strong performance in their respective portfolios. Citi's analysis suggests that these two companies could witness substantial growth, driven by their innovative treatments and the increasing adoption of GLP-1 therapies.
In a recent meeting with executives from Novo Nordisk (NYSE: NVO) and Zealand Pharma, experts noted the strength of Novo's Q3 performance, with potential adjustments to its full-year guidance for 2024. The positive momentum in GLP-1 and insulin-related therapies could lead to further growth for the company, particularly as it continues to ramp up promotional efforts. The success of the direct-to-consumer (DTC) campaign has already been reflected in the company’s market presence, according to Citi experts.
Novo Nordisk is also expected to see encouraging results from ongoing cardiovascular and pivotal trials related to its obesity drug, CagriSema. Feedback from the European Association for the Study of Diabetes (EASD) has been positive, further bolstering the optimistic sentiment surrounding the GLP-1 market. With these developments, the pharmaceutical industry remains focused on the evolving landscape of diabetes and obesity treatments, as companies like Novo Nordisk and Eli Lilly continue to play central roles in addressing these critical health issues.
